{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:27:55Z","timestamp":1785806875884,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi-Pasteur","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novartis Vaccines & Diagnostics"},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.vaccine.2013.03.063","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T04:03:26Z","timestamp":1366171406000},"page":"124-130","source":"Crossref","is-referenced-by-count":73,"title":["Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)"],"prefix":"10.1016","volume":"32","author":[{"given":"Julie A.","family":"Bettinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Scheifele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Vaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duccio","family":"Medini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.03.063_bib0005","first-page":"1","article-title":"Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS)","volume":"36","year":"2009","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0010","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"The disease burden of invasive meningococcal serogroup B disease in Canada","volume":"32","author":"Bettinger","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1126\/science.6823544","article-title":"Cell adhesion molecules","volume":"219","author":"Edelman","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1369-5274(00)00119-3","article-title":"Reverse vaccinology","volume":"3","author":"Rappuoli","year":"2000","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0030","doi-asserted-by":"crossref","first-page":"B42","DOI":"10.1016\/j.vaccine.2009.05.001","article-title":"Meningococcal protein antigens and vaccines","volume":"27","author":"Feavers","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0035","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1586\/erv.09.104","article-title":"Choosing isolates for the evaluation of meningococcal protein vaccines","volume":"8","author":"Feavers","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.03.063_bib0040","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0045","series-title":"Biggest advance against meningitis in 30 years: new jab approved which could save thousands of lives","author":"Gregory","year":"2013"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0050","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.vaccine.2005.01.056","article-title":"Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B","volume":"23","author":"Pillai","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.03.063_bib0060","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(09)70324-X","article-title":"Serogroup B meningococcal vaccines \u2013 an unfinished story","volume":"10","author":"Sadarangani","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0070","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0075","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0080","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/JCM.06835-11","article-title":"Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003","volume":"50","author":"Zhou","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0050659","article-title":"The changing epidemiology of meningococcal disease in Quebec, Canada, 1991\u20132011: potential implications of emergence of new strains","volume":"7","author":"Gilca","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/pch\/14.1.33","article-title":"IMPACT after 17 years: lessons learned about successful networking","volume":"14","author":"Scheifele","year":"2009","journal-title":"Paediatr Child Health"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0095","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/INF.0b013e31819040e7","article-title":"The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada","volume":"28","author":"Bettinger","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0100","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1155\/2009\/871071","article-title":"Profile of serogroup Y meningococcal infections in Canada: implications for vaccine selection. For the members of the Canadian Immunization Monitoring Program, Active (IMPACT)","volume":"20","author":"Le Saux","year":"2009","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0105","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"Maiden","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0110","unstructured":"Jolley KA, Maiden MC. In: Oxford Uo, editor. Neisseria Multi Locus Sequence Typing website. Wellcome Trust and European Union; 2012-09-26."},{"key":"10.1016\/j.vaccine.2013.03.063_bib0115","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0120","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2009.02.098","article-title":"Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus","volume":"27","author":"Bambini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0125","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","author":"Plikaytis","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0130","doi-asserted-by":"crossref","unstructured":"Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. PRedicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infectious Diseases 2013; in Press.","DOI":"10.1016\/S1473-3099(13)70006-9"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1139\/w01-008","article-title":"The panmictic nature of Neisseria meningitidis serogroup B during a period of endemic disease in Canada","volume":"47","author":"Ashton","year":"2001","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0140","series-title":"18th international pathogenic Neisseria conference, P276","first-page":"427","article-title":"Meningococcal Antigen Typing System (MATS) was a conservative estimate of killing when confirmed in a serum bactericidal assay using human complement (hSBA)","author":"Biolchi","year":"2012"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0145","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/JB.06161-11","article-title":"In the NadR regulon, adhesins and diverse meningococcal functions are regulated in response to signals in human saliva","volume":"194","author":"Fagnocchi","year":"2012","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2013.03.063_bib0150","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/424464","article-title":"Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease","volume":"190","author":"Litt","year":"2004","journal-title":"J Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.03.063_bib0155","doi-asserted-by":"crossref","first-page":"B67","DOI":"10.1016\/j.vaccine.2011.12.126","article-title":"The challenge of post-implementation surveillance for novel meningococcal vaccines","volume":"30","author":"Snape","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300409X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300409X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T09:42:49Z","timestamp":1588844569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1300409X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0264410X1300409X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.063","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}